PRP Injections for Thumb Arthritis: Does Platelet-Rich Plasma Work for CMC Joint Pain?
- 6 days ago
- 7 min read
Written by Dr. Jeffrey Peng, MD — Board-Certified Sports Medicine Physician
Published: March 2, 2026 | Last Updated: March 2, 2026
Thumb carpometacarpal (CMC) joint osteoarthritis is one of the most common and debilitating forms of hand arthritis, affecting millions of people—particularly women over the age of 50. The CMC joint sits at the base of the thumb where it meets the wrist, and it is responsible for the wide range of motion that allows you to grip, pinch, and perform fine motor tasks like opening jars, turning keys, or holding a pen. When the cartilage in this joint wears down, it leads to pain, swelling, stiffness, and sometimes visible deformity, significantly impacting daily function and quality of life.
Traditional treatments for thumb arthritis include splinting, anti-inflammatory medications, corticosteroid injections, and in severe cases, surgery. However, many patients find these options either only partially effective or overly invasive. That is why emerging therapies like platelet-rich plasma (PRP) injections are generating interest among both patients and clinicians. In my practice, I regularly treat patients with thumb arthritis who are looking for alternatives to cortisone shots and surgery, and PRP has become an important part of that conversation.
In this article, I review the latest systematic review and meta-analysis on PRP injections for thumb CMC joint osteoarthritis, break down the key findings on pain relief, hand function, and safety, and discuss what this research means for patients exploring non-surgical treatment options.
Watch the Full Video
What Is Thumb CMC Joint Arthritis?
The thumb carpometacarpal joint, also known as the trapeziometacarpal joint, connects the trapezium bone of the wrist to the first metacarpal bone of the thumb. This unique saddle-shaped joint allows the thumb to move in multiple directions—opposition, flexion, extension, and rotation—making it essential for virtually every gripping and pinching task we perform throughout the day.
Unfortunately, the CMC joint is also one of the most common sites for osteoarthritis in the hand. As the cartilage degrades, the bones begin to rub against each other, leading to chronic pain, inflammation, weakness, and functional limitation. Radiographic studies have shown that thumb base osteoarthritis affects up to one-third of postmenopausal women, making it a widespread and clinically significant condition (Tenti et al., 2021).
Why Are Patients Looking Beyond Traditional Treatments?
Standard nonsurgical treatments for thumb CMC arthritis include thumb spica splinting to support and immobilize the joint, oral anti-inflammatory medications, hand therapy, and corticosteroid injections for temporary pain relief. In more advanced cases, surgical options such as joint reconstruction or fusion may be recommended.
However, many of these approaches have limitations. Corticosteroid injections, for example, typically provide only short-term relief lasting a few weeks to months, and there is growing concern that repeated steroid injections may actually accelerate cartilage degeneration over time. Surgery, while effective in severe cases, permanently alters the anatomy of the hand and carries inherent risks. In my practice, I see many patients who fall into the gap between conservative treatments that are not providing adequate relief and surgery that they are not yet ready for—and that is exactly where PRP may have a role to play.
How Does PRP Work for Joint Arthritis?
Platelet-rich plasma is produced by drawing a small amount of the patient’s own blood and processing it in a centrifuge to concentrate the platelets and their associated growth factors. These concentrated growth factors—including transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and others—play a key role in tissue healing and inflammation modulation.
When injected into an arthritic joint, PRP aims to reduce inflammation, promote tissue repair, and potentially support the health of the remaining cartilage. The goal is to shift the joint environment from one that is chronically inflamed and degenerating to one that is more balanced and conducive to healing. PRP has been studied extensively in larger joints such as the knee and hip, where it has shown promising results for reducing pain and improving function. More recently, researchers have begun investigating whether similar benefits can be achieved in smaller joints like the thumb CMC.
What Does the Latest Research Show? A 2025 Systematic Review
A comprehensive systematic review and meta-analysis published in 2025 by El Sewify et al. in the Journal of Hand Microsurgery synthesized the current evidence on PRP injections for thumb CMC osteoarthritis. This review included seven studies with a total of 115 patients receiving PRP treatment. The patient population was predominantly female (67%) with an average age of approximately 62.6 years, and most cases involved moderate to advanced arthritis.
On average, patients received about 1.4 PRP injections per thumb joint, spaced approximately three weeks apart, with a mean follow-up period of 14.1 months. The studies employed various imaging guidance techniques—including ultrasound and fluoroscopy—to ensure accurate needle placement within the small CMC joint. Control groups in the included studies received corticosteroids, normal saline, or hyaluronic acid injections for comparison.
Key Findings: Pain Relief, Function, and Safety
The meta-analysis revealed several important findings regarding PRP for thumb arthritis:
Significant Pain Reduction: Across nearly 100 patients analyzed, PRP injections led to a statistically significant reduction in pain scores. This is a meaningful finding because thumb CMC arthritis pain is often sharp, persistent, and particularly disabling given the thumb’s central role in hand function (El Sewify et al., 2025).
Improved Pinch Strength: Patients treated with PRP demonstrated statistically significant improvements in pinch strength—a critical functional measure for tasks involving the thumb. However, overall grip strength did not show a significant change, which is not entirely unexpected given that grip involves the entire hand and forearm musculature rather than just the thumb CMC joint.
High Patient Satisfaction: Approximately 73.7% of PRP-treated patients reported being satisfied with their outcomes, and all PRP-treated patients were able to resume their prior activities of daily living.
Excellent Safety Profile: PRP was very well tolerated across all included studies. No adverse events directly attributable to PRP were reported. The only complication noted was a single case of a palmar wrist ganglion cyst, which is unlikely to be related to the PRP injection itself.
How Does PRP Compare to Corticosteroid Injections?
One of the most clinically relevant questions for patients is how PRP stacks up against the more commonly used corticosteroid injections. A prospective randomized controlled trial by Malahias et al. (2021) published in Cartilage directly compared PRP to corticosteroid injections in 33 patients with thumb CMC arthritis. While both groups showed improvement at 3 months, the PRP group demonstrated significantly better outcomes at 12 months in terms of pain scores (VAS), functional disability (Q-DASH), and patient satisfaction.
This finding is consistent with what we see in the broader PRP literature for joint arthritis: corticosteroids tend to provide relatively rapid but short-lived relief, while PRP may offer more sustained improvement over the course of 6 to 12 months. In my practice, I discuss these trade-offs with patients, particularly those who have already experienced diminishing returns from repeated cortisone injections.
Additional Evidence Supporting PRP for Thumb Arthritis
A retrospective study from the Mayo Clinic by Hasley et al. (2023) published in Archives of Rehabilitation Research and Clinical Translation evaluated 19 patients who received PRP injections for thumb CMC osteoarthritis. The results showed that 68.8% of treated joints had moderate or excellent symptom improvement, with a mean patient-reported duration of benefit of 15.6 months. No major complications were attributed to the procedure. These findings further support PRP as a safe and potentially effective treatment option for this challenging condition.
Important Limitations to Consider
While these results are encouraging, it is important to interpret them with appropriate caution. The current body of evidence has several limitations that should be acknowledged:
First, the overall number of patients studied remains relatively small. The El Sewify meta-analysis included only 115 PRP-treated patients across seven studies, which limits the statistical power and generalizability of the findings.
Second, there is significant heterogeneity in how PRP is prepared and administered across studies. Different PRP preparation systems, platelet concentrations, leukocyte content, injection techniques, and treatment protocols make it difficult to directly compare results. Standardized protocols for PRP preparation and administration in small joints have not yet been established.
Third, the majority of included studies were not placebo-controlled, double-blind trials—the gold standard for establishing treatment efficacy. This means that placebo effects and other biases may contribute to some of the observed improvements.
Further large-scale, randomized, placebo-controlled trials are needed to definitively establish the role of PRP in thumb CMC arthritis treatment and to optimize treatment protocols.
Who Might Be a Good Candidate for PRP Thumb Injections?
Based on the current evidence and my clinical experience, PRP injections for thumb CMC arthritis may be most appropriate for patients who have mild to moderate thumb osteoarthritis and have not responded adequately to conservative treatments like splinting and therapy, patients who have experienced diminishing returns from repeated corticosteroid injections and are looking for a longer-lasting alternative, and patients who wish to delay or avoid surgical intervention while still pursuing active treatment.
It is worth noting that PRP may be less effective in very advanced, end-stage arthritis where there is minimal cartilage remaining. The best candidates tend to be those with earlier-stage disease where there is still biological potential for the growth factors to exert their therapeutic effects.
The Bottom Line
PRP injections represent a promising non-surgical treatment option for patients with thumb CMC joint osteoarthritis. The latest systematic review demonstrates statistically significant pain reduction, improved pinch strength, high patient satisfaction, and an excellent safety profile. While more high-quality research is needed—particularly larger randomized controlled trials with standardized PRP protocols—the current evidence suggests that PRP is a reasonable option to discuss with your doctor, especially if traditional treatments have not provided adequate relief.
If you are experiencing thumb base pain that is limiting your daily activities and want to learn more about whether PRP injections may be right for you, I encourage you to schedule a consultation with a sports medicine physician or orthopedic specialist who has experience with orthobiologic therapies.
References
1. El Sewify O, Datta S, Legler J, Sylvain M, Cheah A, Efanov JI. Safety and efficacy of platelet-rich plasma injections in basal thumb osteoarthritis; should we offer it or not? J Hand Microsurg. 2025;17(3):100223. doi: 10.1016/j.jham.2025.100223
2. Malahias MA, Roumeliotis L, Nikolaou VS, Chronopoulos E, Sourlas I, Babis GC. Platelet-rich plasma versus corticosteroid intra-articular injections for the treatment of trapeziometacarpal arthritis: a prospective randomized controlled clinical trial. Cartilage. 2021;12(1):51-61. doi: 10.1177/1947603518805230
3. Hasley IB, Bies MM, Hollman JH, Carta KG, Sellon JL, Brault JS. Platelet-rich plasma injection for thumb carpometacarpal joint osteoarthritis. Arch Rehabil Res Clin Transl. 2023;5(1):100257. doi: 10.1016/j.arrct.2023.100257
4. Tenti S, Cheleschi S, Mondanelli N, Giannotti S, Fioravanti A. New trends in injection-based therapy for thumb-base osteoarthritis: where are we and where are we going? Front Pharmacol. 2021;12:637904. doi: 10.3389/fphar.2021.637904
Disclaimer: This article is for educational purposes only and does not substitute for the medical advice of a physician. The information presented reflects the opinions of Dr. Jeffrey Peng and does not represent the views of any affiliated institutions or hospital systems. Always consult with your healthcare provider before making decisions about your treatment. Individual results may vary.
Comments